NEW YORK (GenomeWeb News) – Enzo Biochem will seek CLIA waivers for GeneNews' colorectal cancer test in New York and New Jersey and market the test in those states, under an agreement announced by the firms today.

Enzo plans to validate and seek approval in New York, New Jersey, and under CLIA requirements for the ColonSentry blood-based test for colorectal cancer risk. It also intends to market and secure third-party reimbursement for the test. Enzo said it hopes to make the test available in the second half of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.